These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10101692)

  • 21. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 22. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Gambassi G; Landolfi R; Bernabei R
    N Engl J Med; 1997 Oct; 337(17):1243-4. PubMed ID: 9340528
    [No Abstract]   [Full Text] [Related]  

  • 23. In the era of stabilize and seal, is there a role for GP IIb/IIIa agents in PCI?
    Gilchrist IC
    Catheter Cardiovasc Interv; 2010 May; 75(6):903-4. PubMed ID: 20432396
    [No Abstract]   [Full Text] [Related]  

  • 24. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Khan SS; Forrester J
    N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
    [No Abstract]   [Full Text] [Related]  

  • 25. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet GP IIb/IIIa inhibition in myocardial infarction treated by coronary stenting: ready for prime time.
    Anderson HV
    J Invasive Cardiol; 2000 Mar; 12(3):140-1. PubMed ID: 10877555
    [No Abstract]   [Full Text] [Related]  

  • 27. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS; Anderson K; Weisman HF
    Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
    Moliterno DJ; Ziada KM
    J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681
    [No Abstract]   [Full Text] [Related]  

  • 29. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
    Reginelli JP; Topol EJ
    Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
    [No Abstract]   [Full Text] [Related]  

  • 30. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 31. Minimally invasive bypass surgery.
    Dragu RE
    N Engl J Med; 2002 Dec; 347(26):2165-8; author reply 2165-8. PubMed ID: 12501850
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of angioplasty with stenting in acute myocardial infarction.
    Herrmann HC
    N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478
    [No Abstract]   [Full Text] [Related]  

  • 33. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F
    Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
    [No Abstract]   [Full Text] [Related]  

  • 34. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 35. Future trials of antiplatelet agents in cardiac ischemia.
    Throckmorton DC
    N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432
    [No Abstract]   [Full Text] [Related]  

  • 36. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Rescue platelet glycoprotein IIb/IIIa inhibitor therapy in thrombosis complicating superficial femoral artery angioplasty.
    Grollman JH; Coil A
    Cardiovasc Intervent Radiol; 2002; 25(1):77-80. PubMed ID: 11907783
    [No Abstract]   [Full Text] [Related]  

  • 38. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 39. [Should treatment with glycoprotein IIa/IIIb receptor blocker be controlled in patients undergoing coronary intervention?].
    Heras M
    Rev Esp Cardiol; 2001 Nov; 54(11):1251-3. PubMed ID: 11707232
    [No Abstract]   [Full Text] [Related]  

  • 40. [GPIIb/IIIa inhibitor].
    Ikeda Y
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1174-81. PubMed ID: 10771692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.